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Abstract
Background: Intravenous drug users (IVDU) have a 10-fold increased risk of community-acquired
pneumonia (CAP) compared to the general population. There is scarce data available evaluating the
clinical outcomes of IVDU hospitalized patients with CAP and that data mostly focuses on mortality.
The objective of this study was to evaluate the clinical characteristics, incidence and outcomes of
hospitalized patients with CAP in active intravenous drug users in Louisville, Kentucky.
Methods: This was a secondary data analysis of the University of Louisville Pneumonia study.
IVDU patients were propensity score matched to a non-IVDU group. Study outcomes were time to
clinical stability (TCS), length of stay (LOS), mortality at discharge, and mortality at 1 year. Stratified
Cox proportional hazard regression was performed to evaluate TCS and LOS. Conditional logistic
regression was performed to evaluate mortality. Statistical significance was defined as p ≤ 0.05.
Results: From a total of 8,284 hospitalized patients with CAP reviewed, 113 patients were matched
per group. Median (IQR) age for the IVDU was 33 (28-43) versus 36 (28-48) for the matched nonIVDU group (p<0.001). Analysis showed no association with TCS (stratified hazard ratio (sHR): 0.81;
95% CI: 0.58-1.14; p=0.227), LOS (sHR: 0.71; 95% CI: 0.50-1.01; p=0.053), mortality at discharge
(conditional odds ratio (cOR): 1.67; 95% CI: 0.40-6.97; p=0.484) and mortality at 1 year (cOR: 1.125;
95% CI: 0.43-2.92; p=0.808).
Conclusions: This study shows that active IVDU hospitalized patients with CAP do not have worse
outcomes when compared with non-IVDU hospitalized patients with CAP. Patients in the IVDU group
were significantly younger. Since severity scores commonly used are heavily influenced by age,
these will not likely be useful tools to assist the physicians with the site for care and management.
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Introduction
Opioid use has reached epidemic proportions in the US with
the State of Kentucky ranking third in the country for ageadjusted rates of drug overdose deaths[1]. The highest overdose
deaths in Kentucky were reported in the city of Louisville [2].
Infectious diseases are a major cause of morbidity and mortality
among intravenous drug users (IVDU)[3-6]. Malnutrition,
immunodeficiency, homelessness and needle sharing play a
major role in this groups increased risk.
Community-acquired pneumonia (CAP) is one of the most
serious infectious complications that has been described in
IVDU [7-10]. IVDU has also been associated with greater
severity of CAP which may be evident by the development of
empyema, complicated parapneumonic effusion, or need of
mechanical ventilation [11, 12].

Despite the knowledge of IVDU being at increased risk of
acquiring pneumonia, there are no studies evaluating if
intravenous drug use is associated with poor outcomes in
hospitalized patients with CAP. The objectives of this study were
to compare hospitalized patients with CAP who are active IVDU
to patients with no history of active IVDU in regards to clinical
characteristics and clinical outcomes.

Methods
Study Design & Study Population
This was a case control study. The cases, hospitalized patients
with IVDU, and controls, hospotalized patients without IVDU
were obtained performing a secondary data analysis of the
University of Louisville Pneumonia study, a prospective
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population-based cohort study of all hospitalized adults with
CAP who were residents in the city of Louisville, Kentucky, from
June 1st, 2014 to May 31st, 2016 [13].

Table 1 Patients’ characteristics for both study groups

Inclusion Criteria
Diagnosis of CAP required the presence of criterion A, B, and C:
A. New pulmonary infiltrate on imaging (CT scan or chest
x-ray) at the time of admission to the hospital.
B. Signs and Symptoms of CAP (at least one of the following):
•
New or increased cough
•
Fever >37.8°C (100.0°F) or hypothermia <35.6°C
(96.0°F)
•
Changes in WBC (leukocytosis >11,000 cells/mm3,
left shift > 10% band forms/microliter, or leukopenia
< 4,000 cells/mm3
C. Working diagnosis of CAP at the time of hospital admission
with antimicrobial therapy given within 24 hours of
admission.

Demographics

Variable

IV
Drug Users

Non IV
Drug Users

Total Population

n=113

n=113

Age, median (IQRa)

33 [28, 43]

36 [28, 48]

0.364

Male sex, n (%)

66 (58)

70 (62)

0.684

Black or African American Race, n (%)

9 (8)

6 (5)

0.593

BMI ≥ 30

20 (18)

22 (20)

0.864

HIV infection

3 (3)

1 (1)

0.614

Renal disease

17 (15)

10 (9)

0.218

Liver disease

47 (42)

37 (33)

0.215

Congestive heart failure

3 (3)

3 (3)

>0.999

Chronic obstructive pulmonary disease

23 (21)

30 (27)

0.346

Stroke

5 (4)

4 (4)

>0.999

Current Smoker

100 (89)

103 (91)

0.660

Diabetes mellitus

9 (8)

5 (4)

0.408

Cirrhosis

6 (5)

7 (6)

>0.999

Alcohol use

21 (19)

27 (24)

0.416

Nursing home resident

3 (3)

2 (2)

>0.999

Hospitalized within 90 days

24 (21)

14 (12)

0.109

IV antibiotics within 90 days

15 (13)

7 (6)

0.116

Home infusion

0 (0)

3 (3)

0.245

Chronic dialysis

3 (3)

0 (0)

0.245

Study Variables
•
Patients’ characteristics: demographics, medical and social
history, physical, and laboratory findings were collected if
documented in the medical records.
•
Severity of disease: assessed by the following variables –
acute altered mental status on admission, need of intensive
care, ventilatory support, or vasopressor on the day of
admission, pneumonia severity index risk class IV or V.
•
Complications: defined as the presence of persistent
bacteremia and/or endocarditis.

Home wound care

1 (1)

1 (1)

>0.999

Oral antibiotics within 30 days

13 (12)

20 (18)

0.258

Neoplastic disease within past year

0 (0)

7 (6)

0.021

Pneumonia vaccination

16 (14)

20 (18)

0.586

Flu vaccination

16 (14)

23 (20)

0.305

Study Outcomes
•
Time to clinical stability (TCS): A patient was defined as
clinically stable the day that the following four criteria were
met:
1.
Improvement in cough and shortness of breath
2. Lack of fever for at least 8 hours
3. Improving leukocytosis (decreased at least 10% from
the previous day)
4. Tolerating oral intake with adequate gastrointestinal
absorption
Patients were evaluated daily within the first 7 days of
hospitalization to determine the day when clinical stability
was reached.

Medical and Social History, n (%)

Study Groups
Cases (group 1): Hospitalized patients with CAP with active
IVDU documented in the medical record.
Controls (group 2): Hospitalized adults with CAP who did not
have documentation of actively using intravenous drugs.
IVDU cases were matched 1:1 to control cases by age, race, and
history of obesity (body mass index >30), current smoker, active
alcohol use, chronic obstructive pulmonary disease, congestive
heart failure, stroke, diabetes mellitus, HIV, renal disease, and
liver disease.

•

Physical Exam Findings, median (IQR)
Temperature (Degrees Celsius)

37 [37, 38]

37 [37, 38]

0.231

Respiratory rate (Breaths/Minute)

24 [20, 30]

20 [20, 26]

0.008

Systolic blood pressure (mmHg)

106 [92, 121]

112 [97, 127]

0.094

Diastolic blood pressure (mmHg)

58 [49, 68]

61 [54, 73]

0.055

Heart rate (Beats/Minute)

116 [106, 131]

113 [97, 125]

0.047

Serum bicarbonate (mEq/L)

25 [22, 27]

25 [22, 28]

0.611

Blood Urea Nitrogen (mg/dL)

14 [9, 20]

12 [9, 15]

0.077

Serum glucose (mg/dl)

132 [116, 165]

122 [104, 146] 0.012

Hematocrit (%)

36 [33, 40]

38 [34, 42]

Serum sodium (mEq/L)

136 [133, 139] 137 [134, 140]

0.190

Acute altered mental status on
admission

33 (29)

18 (16)

0.026

Need of intensive care on admission

37 (33)

20 (18)

0.014

Need of ventilatory support on
admission

21 (19)

15 (13)

0.363

Need of vasopressors on admission

6 (5)

3 (3)

0.496

Pleural effusion

19 (17)

21 (19)

0.862

35 (31)

26 (23)

0.231

Laboratory Findings, median (IQR)

Length of hospital stay (LOS): defined in days and
calculated for each patient as the day of discharge minus
the day of admission. Patients hospitalized for >14 days
and patients who died prior to 14 days were censored at
14 days.
Mortality: defined as death by any cause 1) during
hospitalization and 2) at one year after discharge.

0.061

Severity of Disease, n (%)

PSI Risk Class IV or V

b

IQR: Interquartile range
b
PSI: pneumonia severity index
a

•

Pvalue
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Statistical Analysis
Descriptive statistics were performed, with comparisons
between groups analyzed by using a Chi-squared test or Fisher’s
exact test for categorical data and the Wilcoxon-Mann-Whitney
U test for continuous data. Kaplan Meier curves were created for
TCS and LOS. Differences in outcomes adjusting for propensity
score matching were analyzed using stratified Cox proportional
hazards regression for TCS and LOS and conditional logistic
regression for mortality during hospitalization and at one year.
Differences are reported as stratified hazard ratios (sHR) or
conditional odds ratios (cOR), respectively.

Results
A total of 113 patients with active IVDU and 113 patients matched
controls were enrolled in the study.
Patients’ characteristics are shown in Table 1. Significant
higher rates of acute altered mental status and need of intensive
care were found in the IVDU group.
The IVDU group was found to have significantly more persistent
bacteremia (20% vs. 1%, p < 0.001), significantly more
endocarditis (14% vs 1%, p < 0.001), and significantly more
pulmonary emboli (15% vs 1%, p < 0.001) than the non-IVDU
group. Image characteristics compatible with septic emboli were
seen in 10% of patients in the IVDU group compared to 0% in
the non-IVDU group (p <0.001).
The top two organisms were Staphylococcus aureus (23% [35
patients] in the IVDU group versus 3% [275 patients] in the nonIVDU group, p= <0.001) and Streptococcus pneumoniae (3% in
both groups, p= 0.438) as shown in Table 2. IVDU had higher
rates of Methicillin-resistant Staphylococcus aureus (MRSA)
and Methicillin-susceptible Staphylococcus aureus (MSSA)
among positive cultures, (37% versus 11% and 25% versus 5%,
respectively). In the IVDU group, MRSA was obtained from 11
blood cultures, 1 from both blood and sputum cultures and 1
from bronco alveolar lavage (BAL). Also from the IVDU group
MSSA was obtained from 5 blood cultures, 6 from both blood
and sputum cultures and 3 from sputum culture. Among the
non IVDU group MRSA was obtained from 1 blood culture and
1 from BAL. From the control group MSSA was obtained from
1 sputum culture. Antiocrobial susceptibility patterns of these
organisms were not collected.
Median (IQR) TCS was 2 (2, 5) days for IVDU group and 2 (1,
4) days for non-IVDU group (sHR: 0.81; 95% CI: 0.58-1.14;
p=0.227). Kaplan-Meier curves for TCS are shown in Figure 1.
Median (IQR) LOS was 5 (2, 9) days for IVDU group and 4 (2,
6) days for non-IVDU group (sHR: 0.71; 95% CI: 0.50-1.01;
p=0.053). Kaplan-Meier curves for LOS are shown in Figure 2.
Mortality rates during hospitalization were 4% for IVDU group
and 3% for non-IVDU group (cOR: 1.67; 95% CI: 0.40-6.97;
p=0.484). Mortality at one year was 12% for IVDU group and
14% for non-IVDU group (cOR: 1.125; 95% CI: 0.43-2.92;
p=0.808).

Discussion
This study shows that IVDU is not associated with poor
outcomes in hospitalized patients with CAP. The more
aggressive management that these patients may receive upon

Table 2 Microorganisms isolated
Organism

IV
Drug Users, n (%)

Non IV
Drug Users, n (%)

Staphylococcus aureus

29 (72)

3 (18)

Streptococcus other

2 (5)

3 (18)

Streptococcus pneumoniae

2 (5)

4 (24)

Streptococcus pyogenes

2 (5)

0 (0)

Enterobacter spp.

1 (2)

0 (0)

Klebsiella pneumoniae

1 (2)

0 (0)

Pseudomonas aeruginosa

1 (2)

0 (0)

Respiratory Syncytial Virus A

1 (2)

0 (0)

Rhinovirus/Enterovirus

1 (2)

2 (12)

Aspergillus spp.

0 (0)

1 (6)

Coronavirus HKU1

0 (0)

1 (6)

Coronavirus OC43

0 (0)

1 (6)

Mycoplasma pneumoniae

0 (0)

1 (6)

Parainfluenza Virus 4

0 (0)

1 (6)

admission may be the reason for similar outcomes in both
groups despite differences found in the severity of the disease.
To our knowledge, this is the first study evaluating clinical
outcomes in IVDU hospitalized with CAP.
Active IVDU presented with more severe CAP as evidenced by
their higher rates of admission to the intensive care unit and
altered mental status. The higher rates of altered mental status
could be explained by drug overdose and consequent aspiration.
Our findings are in concordance with published data indicating
that active substance abuse is a predictor of more severe
pneumonia and the need for more intensive management.
Considering that IVDU patients tend to be younger, as shown
in our study, scores are heavily influenced by age are those
commonly used to assess severity at presentation to the hospital.
These may not be useful tools to assist physicians in care and
management of IVDU CAP patients.
It has been reported that IVDU patients develop more
complications. In a study evaluating risk factors for
complicated parapneumonic effusion and empyema, IVDU
was independently associated with the development of these
complications [11]. However, in our study, a lower number of
IVDU presented with pleural effusions/empyema. This could
be related to a higher percentage of patients with congestive
heart failure in the non-IVDU group who may have developed
effusions secondary to this baseline comorbidity and not the
pneumonia. IVDU commonly developed persistent bacteremia
and endocarditis, particularly in the tricuspid valve with the
subsequent septic emboli to the lungs [14-16]. Our study also
showed higher rates of persistent bacteremia and pulmonary
embolism, both independently associated with poor outcomes.
There was a higher percentage of patients with chest images
compatible with septic emboli. This could indicate that the
pneumonia is actually a consequence of infective endocarditis
bringing the relevance of obtaining blood cultures on admission
to the hospitals and allowing an early identification of this
population.
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the medical record. Antibiotics prior to enrollment were not
analyzed.
In conclusion, our study shows that IVDU is not associated with
poor outcomes among hospitalized CAP patients. IVDU patients
were significantly younger and presented with more severe CAP
as evidenced by higher rates of admission to the intensive care
unit and altered mental status. These patients also developed
significantly higher complications like persistent bacteremia,
pulmonary emboli and endocarditis. A more aggressive
management may be needed in this young population in order
to achieve good outcomes and prevent further complications.
Figure 1 Kaplan Meier Curves for Time to Clinical Stability
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